tipifarnib has been researched along with Leukemia, Large Granular Lymphocytic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, F; Blaskovich, MA; Chen, X; Djeu, JY; Edwards, TD; Epling-Burnette, PK; Loughran, TP; Moscinski, L; Painter, JS; Sebti, S; Sokol, L; Wei, S; Yoder, JA; Zhou, J; Zou, J | 1 |
| Bai, F; Blaskovich, MA; Connolly, K; Djeu, JY; Epling-Burnette, P; Loughran, TP; Painter, JS; Sebti, S; Sokol, L; Sotomayor, E; Villagra, AV; Wei, S; Zou, J | 1 |
2 other study(ies) available for tipifarnib and Leukemia, Large Granular Lymphocytic
| Article | Year |
|---|---|
Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling.
Topics: Antineoplastic Agents; Cells, Cultured; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Hypertension, Pulmonary; K562 Cells; Leukemia, Large Granular Lymphocytic; Middle Aged; Quinolones; Receptors, Natural Killer Cell; Signal Transduction; Treatment Outcome | 2008 |
Tipifarnib-mediated suppression of T-bet-dependent signaling pathways.
Topics: Acetylation; Adult; Aged; Antineoplastic Agents; Cytokines; Farnesyltranstransferase; Female; Gene Expression Regulation, Neoplastic; Humans; Immunosuppression Therapy; Leukemia, Large Granular Lymphocytic; Male; Middle Aged; Quinolones; Signal Transduction; T-Box Domain Proteins; Th1 Cells; Th1-Th2 Balance; Th2 Cells | 2012 |